Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and activ...
Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-ter...
Key Highlights: Implications: Revahale gives Indian COPD patients—especially older adults and those with severe breathing problems—a simpler, once‑daily nebulized option that doesn’t depend on strong ...
Key Highlights: Implications: By adding the NSE to its existing BSE listing, Fermenta can attract more institutional and retail participation, which may support tighter spr...
Key Highlights: Implications: By consolidating three injectable-focused entities under one legal umbrella, Aurobindo can streamline manufacturing, R&D, and commercial operati...
Key Highlights: Implications: The expansion makes Turbhe more competitive for high-potency peptides, HPAPIs, and biomolecules, helping Piramal attract programs that need safe, sm...
The pharmaceutical industry is entering a new era where innovation is no longer driven by individual organisations alone. From drug discovery and clinical research to manufacturing, regulatory complia...
Key Highlights: Implications: Viatris is selling up to 92 million Biocon shares (about 5.6% of the company) in a secondary sale, so Biocon gets no money from it; the deal is priced at a di...
Latest Developments in Specialty Pharma India’s pharmaceutical industry has built a global reputation as a leading supplier of affordable generic medicines. Over the past two decades, Indian com...
